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INTRODUCTION 51
Hindbrain catecholamine neurons are required components of the brain's glucoregulatory 52 circuitry. Pharmacological (29) , chemical (26, 43) or immunotoxic (35, 40) disruption of these 53 neurons impairs or abolishes key protective responses to glucose deficit induced by hypoglycemic 54 doses of insulin or by central or peripheral blockade of glycolysis using the antimetabolic glucose 55 analogue, 2-deoxy-D-glucose (2DG). Dissection of the hindbrain catecholamine system using the 56 retrogradely transported immunotoxin, anti-dopamine β-hydroxylase conjugated to saporin (DSAP), 57 has revealed distinct responses to glucoprivation that are dependent on hypothalamically and spinally 58 projecting norepinephrine (NE) and/or epinephrine (E) neurons. Specifically, some of those NE and E 59 neurons with processes that innervate the medial hypothalamic region are required for feeding (35) , 60 corticosterone (40) and reproductive responses (15) to glucoprivation. Spinally projecting E neurons 61 that innervate adrenal medullary preganglionic neurons are required for the adrenal medullary response 62 to glucoprivation (35) . These catecholamine-mediated responses comprise a diverse array of 63 behavioral, endocrine and autonomic responses, all of which are involved in prevention of and 64 recovery from glucose deficit. 65
Despite the demonstrated importance of hindbrain NE and E neurons for eliciting key 66 responses to glucose deficit, the glucose sensing mechanisms and circuitry underlying their 67 glucoregulatory functions are poorly understood. Furthermore, a number of drugs that reduce glucose 68 availability or metabolism, but by different mechanisms, have been shown to increase food intake, 69 suggesting the possibility (or likelihood) of multiple glucose-driven feeding systems. Therefore, in the 70 present set of experiments, we address these issues, focusing on control of food intake and blood 71 glucose response. We examine three drugs -glucosamine (GcA), phloridzin (Phl) and 5-thio-D-glucose 72 (5TG) -all known to produce glucose deficit by different mechanisms, to determine whether the 73 signals they generate increase both feeding and blood glucose and whether they require NE or E 74 neurons in order to do this. 75 5TG is an antimetabolic glucose analogue that reduces glucose utilization in all cells. It's most 76 potent antiglycolytic actions are inhibition of phosphoglucomutase and glucose-6-phosphate 77 dehydrogenase but it also inhibits hexokinase (8). GcA inhibits glucokinase (GK), a hexokinase that 78 selectively phosphorylates only glucose, is saturated at high glucose concentration (S 0.5 2 = 5-10 mM 79 glucose) and is not inhibited by its product, glucose-6-phosphate (9, 16). GK is an endogenous 80 glucose-sensing molecule that plays a central role in stimulating insulin secretion when glucose levels 81 rise. GK is distributed sparsely in the brain, but has been detected in areas important for control of food 82 intake (9, 18, 27), including in glucose-excited (GE) and glucose-inhibited (GI) neurons in the 83 hypothalamus (9) and nucleus of the solitary tract (NTS) (2). Phl is the classic sodium-linked glucose 84 transporter (SGLT) antagonist (10). SGLTs transport glucose across cell membranes against the 85 glucose concentration gradient by coupling with down-gradient transport of Na + . Phl reduces glucose 86 entry only into cells that express the SGLT receptor. The latter include some hypothalamic neurons of 87 both the GE and GI type (6, 12, 31) . These neurons respond to changes in extracellular glucose, but are 88 not responsive to GcA, alloxan, or N-acetyl-D-glucosamine and do not express GK. Because the 89 response of SGLT-expressing neurons to antimetabolic glucose analogues mimics the effect of 90 glucose, this transporter has been described as a nonmetabolic glucose sensor, possibly serving to 91 inform the brain about ambient extracellular glucose levels (6, 12) . 92
In the experiments reported here, we examine the importance of hindbrain catecholamine 93 neurons for GcA-, Phl-and 5TG-induced feeding and the adrenal medullary hyperglycemic response 94 using animals in which hypothalamically-projecting NE and E neurons were retrogradely lesioned by 95 medial hypothalamic injection of DSAP. Since both lateral and fourth ventricle (LV and 4V, 96 respectively) injections of GcA, Phl and 5TG have been demonstrated to increase food intake (11, 34, 97 44, 45) , suggesting the possibility that these drugs may act at multiple sites to produce their 98 glucoregulatory actions, we tested both LV and 4V injections of these agents in this study. Lastly, we 99 examined the dependence of GcA-, Phl-and 5TG-induced feeding on the mitogen activated protein 100 Screening test for lesion effectiveness. As an initial screening test to assess effectiveness of 126 the DSAP lesion, SAP and DSAP rats were tested for 2DG-induced feeding, a response that is 127 impaired by this lesion (35). 2DG (200 mg/kg body weight in 0.9% sterile saline; Sigma-Aldrich) or 128 0.9% saline (control) was injected subcutaneously at approximately 9:00 AM and food intake was 129 measured during the subsequent four hours. Any DSAP rat that ate more that 2.0 g of food after 2DG 130 injection was eliminated from the study. At the end of experiments, the lesion was analyzed further by 131 quantifying dopamine β-hydroxylase (DBH)-immunoreactive cell bodies in hindbrain catecholamine 132 cell groups, as described below. To be included in the data analysis, DSAP rats were required to have a 133 reduction of at least 70% in DBH cell numbers in A1, A1/C1 and C1m, compared to the respective 134 averages in SAP rats. Overall about 90 % of rats had successful lesions. 1.0 mm caudal to bregma, 1.5 mm lateral to midline and 3.9 mm ventral to the brain surface (33). 145 Beginning one week later, feeding and blood glucose tests were conducted after delivery of drug or 146 vehicle into the 4V or LV over a 5-min period using a Gilmont micrometer syringe (Cole-Parmer, 147
Vernon Hills, IL). 148
The patency and correct placement of 4V cannulas was assessed by measuring tail blood 149 glucose levels before and 60 min after 4V 5TG (135 µg/3 µl) (34) using a FreeStyle glucose monitor. 150 LV cannulas were assessed using angiotensin II (50 ng/3µl/rat; Sigma-Aldrich)-induced water intake 151 (17). Only rats that increased blood glucose levels to at least 150% of control within 60 min after 4V 152 5TG injection or drank at least 6 ml within 15 min of LV angiotensin II and that had cannula 153 placements verified histologically as being correct were included in the data analysis. Overall about 154 90% of 4V and LV cannulas were correctly positioned. 155
156
Measurements of food intake and blood glucose. Food intake was measured in DSAP lesioned rats 157 and SAP controls in 4-hr tests after injection of 5TG, GcA, Phl or the respective vehicle into the LV or 158 4V. GcA (Sigma-Aldrich, St. Louis, MO) was dissolved in artificial cerebral spinal fluid (aCSF) and 159 injected into the LV and 4V at 0.2 or 0.6 mg in 3 µl, or 1.0 mg in 5 µl (32). The composition of aCSF 160 (in mM) were NaCl (128), KHCO3 (3.1), Mg2Cl2 (1), NaHCO3 (21.4), CaCl2 (1.2), and glucose 161 (2.8). Phl was dissolved in 50% DMSO in saline and injected at 56.25, 112.5 and 224.0 µg/3 µl/rat. 162 5TG (135 µg) was injected in 3 µl of aCSF. In the same rats on separate test days, blood glucose 163 concentrations were measured in the absence of food before and during a 2-hr or 5-hr period after 164 intraventricular drug injection. Glucose was measured from tail blood using a FreeStyle glucose 165 monitor (Abbot Diabetes Care, Alameda, CA. Body weights were measured on the test days. Average 166 body weight in the different experimental groups ranged from 410 to 478 g, and there were no 167 significant differences between treatment groups (P's > 0.09). Testing was begun one week after LV or 168 4V cannula implantation and completed 3-4 wks later. Drug tests were separated by at least one week. 169
To examine the involvement of the MEK/ERK signaling cascade in responses to these different 170 glycemic challenges, an inhibitor of this pathway, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-171 aminophenylthio]butadiene, 1.0 or 6.0 µg/2 µl/rat) or 2 μl of the solvent (50% DMSO in saline) was 172 injected into the 4V, 30 min before injection of GcA (0.6 mg/rat), 5TG (135 µg/rat), Phl (112.5 µg/rat) 173 or vehicle solutions into the 4V. Feeding and blood glucose tests were performed on separate test days, 174
Immunohistochemistry. After completion of testing, rats were euthanized by deep isoflurane-176 induced anesthesia (Halocarbon Products). Just before cessation of the heartbeat, rats were perfused 177 transcardially with cold PBS (pH 7.4) followed by freshly-made cold 4% formaldehyde in PBS. After 178 perfusion, brains were rapidly removed and placed in 4% formaldehyde/PBS at 4°C overnight, then 179 transferred to 12.5% and 25% sucrose in PBS for 24 hr each, then sectioned coronally on a cryostat at 180 40 µm thickness, collected into serial sets for immunohistochemical processing and for examine of 181 cannula placement. Brain sections were stained using standard avidin-biotin-peroxidase 182 immunohistochemical techniques to detect DBH (35). They were incubated with mouse monoclonal 183 anti-DBH (1:20,000; Millipore, San Jose, CA), washed and sequentially incubated biotintylated donkey 184
anti-mouse IgG (1:500; Jackson ImmunoResearch Laboratories) and ExtrAvidin-Peroxidase (1:1,500; 185
Sigma-Aldrich, St. Louis, MO) and reacted with nickel-intensified diaminobenzidine to produce a 186
gray/black reaction product. Catecholamine cell groups are defined as in The Rat Brain in Stereotaxic 187
Coordinates (33). However, we refer here to the middle portion of C1 as C1m, which extends from -188 12.98 to -12.5 mm caudal to bregma. DBH-positive cells were counted bilaterally in three consecutive 189 coronal sections for each region for each rat. Hypothalamic areas were examined to detect presence or 190 absence of DBH terminals in established DBH terminal areas, but these were not quantified. However, 191 all DSAP rats with significant loss of catecholamine neurons in the areas described above also had 192 significant loss of DBH terminals in PVH and medial hypothalamic areas (Fig. 1) Both 4V and LV GcA stimulated food intake ( Fig. 2A) in normal rats in a dose-dependent 203 fashion during the 4-hr test. Intake was increased significantly after both 4V (n = 6 -9 rats/group) and 204 LV (n = 7 -8 rats/group) GcA at 0.6 and 1.0 mg/rat, but was not significantly increased at 0.2 mg/rat 205 (Ps < 0.05 for both 4V and LV compared to their respective aCSF control injections). The two higher 206
GcA doses appeared to be nearly equipotent for stimulation of feeding. PVH SAP controls also 207 increased feeding in response to both 4V (n = 8 -9 rats/group) and LV (n = 6 rats/group) injections of 208
GcA (0.6 mg/rat), compared to their intake after aCSF injection (Ps < 0.01, vs SAP control; Fig. 2B ). 209
PVH DSAP abolished the feeding responses to both 4V and LV GcA injections (Ps > 0.7, vs DSAP 210 control; n = 7 -8, and 8 rats/group for 4V and LV, respectively). 211
GcA injection (0.6 mg/rat) had no effect on blood glucose levels in rats (Fig. 3) during the 5 hr 212 after injection into the 4V (P > 0.8 between groups; n = 5 rats per group) or into the LV (P > 0.2 213 between groups; n = 6 rats per group). 214
Effects of Phl on feeding and blood glucose. 215
Injection of Phl into either the 4V (n = 10 -11 rats/group) or LV (n = 8 -12 rats/group) dose-216 dependently enhanced food intake in rats. Four hour food intake was increased significantly after 217 112.5 and 225 µg/rat, but not after 56.25 µg/rat (Ps < 0.01, vs solvent control for both 4V and LV) and 218 the amount consumed was similar in both LV and 4V groups (Fig. 4A) . PVH SAP controls also 219 increased feeding in response to both LV (n = 6 rats/group) and 4V (n = 8 rats/group) injections of Phl 220 (Fig. 4B ), compared to their intake after solvent injection (Ps < 0.001, vs SAP control). In contrast, 221 PVH DSAP rats failed to increase food intake in response to Phl injection into either LV or 4V (Ps > 222 0.7, vs DSAP control; n = 8 or 9 rats/group for LV, 4V injection, respectively). 223
Blood glucose levels were not altered by injection of Phl (225 µg/rat) into either the LV (P > 224 0.2 between treatments; n = 6 rats per group) or 4V (P > 0.08 between groups; n = 7 rats per group) 225 during 5 hr after the injection (Fig. 5) . 226
Effects of 5TG on feeding and blood glucose. 227
Both LV and 4V 5TG (135 µg/rat) increased feeding significantly in a 4 hr test in SAP rats 228 compared to intake after aCSF injection (Ps < 0.001, SAP 5TG vs SAP saline for both LV and 4V rats; 229 n = 5 -6 and 6 rats per group for 4V and LV injections, respectively), but failed to increase feeding in 230
PVH DSAP rats (P > 0.3, vs SAP controls; Fig. 6 ). However, blood glucose levels in both SAP and 231 DSAP rats were significantly elevated 1 hr after 5TG injection compared to their respective aCSF 232 control injection (Ps < 0.001, vs aCSF; n = 11, and 6 -8 rats per group for 4V and LV injections, 233 respectively). 234
Effects of U0126 on feeding and blood glucose. 235
The MEK inhibitor, U0126, was injected into the 4V, 30 min prior to 4V injection of 5TG (135 236 µg/rat), GcA (0.6 mg/rat), and Phl (112.5 µg/rat). As shown in Fig. 7A , prior injection of U0126 (1 237 µg/rat) completely blocked GcA-induced food intake (P > 0.5, vs control; n = 8 -9 rats per group), but 238 did not reduce the feeding in response to Phl ( Fig. 7B ; P < 0.01, vs control; n = 7 -10 rats per group). 239
Even a higher dose of U0126 (6 µg/rat) failed to block 5TG-induced feeding (Fig. 7C) or 240 hyperglycemia (P < 0.001, vs control; n = 6 rats per group). U0126 was also tested at lower doses and 241 was ineffective in reducing 5TG's feeding and hyperglycemic effects (not shown). 242
243

DISCUSSION 244
Results of these experiments show that GcA, Phl and 5TG all stimulated feeding when injected 245 into either the LV or 4V and, at the doses used here, the potency of each drug was similar at both 246 injection sites. Furthermore, feeding responses to both LV and 4V injections were abolished by 247 retrograde destruction of NE and E neurons innervating the medial hypothalamus, indicating that the 248 feeding responses evoked by all three agents require these NE or E neurons. Earlier pharmacological 249 and biochemical evidence has demonstrated a crucial role for NE and E neurons in glucoprivic feeding 250 (3, 4, 20, 41) . Fos and gene expression data have shown that specific subpopulations of catecholamine 251 neurons are potently activated by 2DG-induced glucoprivation (21, 24, 37) . Gene silencing results 252 have indicated that neuropeptide Y/catecholamine co-expressing neurons are required for the 253 glucoprivic feeding response (22). Previous work has also shown that food intake can be evoked by 254 third ventricle injections of GcA (45), third ventricle (44) and 4V (11) injections of Phl, and both LV 255 and 4V injections of 5TG (34). However, these are the first data indicating that the signals generated 256 by the actions of these drugs interact with and require hindbrain catecholamine neurons for their 257 orexigenic actions. 258
It could be argued that loss of feeding in response to 5TG, Phl and GcA in PVH DSAP lesioned 259 rats results from nonselective behavioral suppression arising from the lesion. However, this possibility 260 is extremely unlikely because repeatedly replicated experimental observations indicate that this DSAP 261 lesion of hindbrain catecholamine neurons does not impair feeding induced by nonglucoprivic stimuli, 262 such as overnight food deprivation, or administration of β-mercaptoacetate, an inhibitor of fatty acid 263 oxidation (14, 35). Further, we recently measured circadian distribution of feeding and activity in rats 264 with this same DSAP lesion and found no differences between DSAP and control groups (23). Hence, 265
this DSAP lesion appears to impair the glucoprivic feeding response without producing nonspecific 266 impairment of feeding or other behaviors. 267
Together these results show that a variety of mechanistically distinct glucose-sensing 268 mechanisms contribute to control of food, but those tested here all require intact hindbrain 269 catecholamine neurons. However, an unanswered question highlighted by the present work is whether 270 catecholamine neurons themselves possess or respond to the glucose-sensing mechanisms activated by 271 these drugs or whether cells sensitive to these drugs alter catecholamine neurons through their neural 272 connectivity. Catecholamine neurons are not homogeneous in phenotype or function and only limited 273 work has been done to evaluate the various subtypes for their glucose sensing capabilities or their 274 expression of known glucose sensing mechanisms. 275
Evidence currently in hand regarding 5TG, GcA and Phl favors the view that their sites of 276 action differ. 5TG, a glucose analogue, which uses cellular glucose transporters and antagonizes 277 glycolysis at a number of steps, has the capability of reducing glucose utilization in all cells. 278 Nevertheless, the brain sites where intraparenchymal nanoliter injections of 5TG are effective in 279 stimulating feeding and counterregulatory responses are limited to specific sites within the hindbrain 280 parenchyma (1, 36). And although both LV and 4V injections of 5TG are effective in stimulating 281 feeding, acute aqueduct occlusion eliminates the response to LV, but does not diminish the feeding 282 response to 4V injections (34), indicating that LV injections are effective due to their diffusion through 283 the ventricular system to receptive sites in the hindbrain. Studies similar to those localizing 5TG's 284 sites of action have not been done for either GcA or Phl. However, both are more limited than 5TG in 285 the cellular mechanisms they target, which also suggests that their anatomical sites of action may differ 286 and may be more limited. GcA blocks glucose utilization only in the subset of cells that express GK 287 (7). GK-immunoreactivity has been identified in periventricular ependymocytes, endothelial cells and 288 in serotonin neurons (28), in tanycytes and periventricular glial cells (42), in hypothalamic neurons (9, 289 12, 18, 27) and in both GE and GI neurons in the NTS (2). In addition, GK may be expressed by some 290 catecholamine neurons. GK transcript has been detected in laser catapult microdissected tissue from 291 the NTS containing A2 and C2 catecholamine cells and the GK message was inducible by 292 hypoglycemia (5). Phl reduces glucose entry only into cells that express the SGLT receptor. Blockade 293 of SGLT has been shown to inhibit activity of GE neurons and to activate SGLT-expressing GI 294 neurons in the hypothalamus (6, 12). The response of these neurons to antimetabolic glucose analogues 295 mimics the effect of glucose. They respond to changes in extracellular glucose, but are not responsive 296 to GcA, alloxan, or N-acetyl-D-glucosamine and do not express GK, suggesting that, at least in some 297 sites, GcA and Phl activate different cells. There is no evidence to date that NE or E neurons express 298
SGLTs. 299
Although the DSAP lesion data reported here suggests that 5TG, GcA and Phl all evoke 300 feeding via a circuit that includes hindbrain catecholamine neurons, it should be noted that medial 301 hypothalamic DSAP injections presumably destroy multiple subpopulations of functionally distinct 302 catecholamine neurons with projections to the hypothalamus. Thus, it may be that each of these agents 303 either directly or indirectly activates different catecholamine subpopulations. Indeed, utilization of 304 several different mechanisms of glucose sensing would seem adaptive for controlling food intake over 305 a wide range of glucose concentrations. For example, Phl may stimulate feeding by suppressing 306 activation of SGLT-expressing GE neurons whose normal role perhaps is to inhibit feeding, or by 307 activating GI neurons. Similarly, the fact that GK has a low affinity for glucose (7, 16), requiring 308 glucose concentrations for activation that are much higher than normal brain glucose levels, suggests 309 that GK may control food intake during daily meals, most of which that occur at blood glucose levels 310 that are within the normal range, or that it may sustain feeding after glucose levels have risen during a 311 feeding bout. Control of feeding by GK-expressing neurons thus might be important under normal 312 conditions in averting hypoglycemia by stimulating feeding prior to glucoprivic emergency. In 313 contrast, rapid and profound glucoprivation would appear to require a fail-safe system with strong 314 activation of neurons capable of eliciting feeding responses to repair glucose deficit and must do this 315 without regard to availability of metabolic fuels that cannot be utilized by the brain. Research 316 addressing such questions will significantly enhance our understanding of the overall role of glucose in 317 controlling of food intake. 318 AMP-activated protein kinase (AMPK) is a highly conserved kinase that is activated 319 (phosphorylated) in response to increased ADP/ATP ratio, a characteristic that enables it to act as an 320 energy sensor in some cells. Food deprivation activates AMPK and food intake can be decreased or 321 increased by drugs that enhance or block AMPK activation (13). Therefore, our previous studies of 322 AMPK (25) are of interest in the present context. We found that 2DG increased phosphorylation of 323 AMPKα subunits at Thr172 in micropunches from the ventrolateral medullary area containing 324 catecholamine cell groups A1 and C1, but not in punches from immediately adjacent 325 noncatecholaminergic regions. However, 2DG did not increase AMPK phosphorylation in this same 326 tissue site in rats with PVH DSAP lesions that destroyed the catecholamine neurons located there. 327
These results suggest yet another energy sensing mechanism that may activate hindbrain 328 catecholamine neurons and contribute to their effects on food intake. 329
In contrast to food intake, of the three agents tested in the present study, only 5TG triggered a 330 hyperglycemic response, suggesting that the glucose-sensing mechanisms controlling blood glucose 331 responses differ from those controlling food intake and, in addition, that the blood glucose response 332 depends specifically on sensing of glycolysis. The fact that GcA and Phl stimulated food intake, but 333 did not alter blood glucose is consistent with early reports. In studies using central administration of 334 alloxan, a GK inhibitor and pancreatic beta cell toxin, we demonstrated that a low 4V dose of alloxan 335 evoked feeding, but did not trigger hyperglycemia (39). In addition, we found that high LV or 4V 336 doses impaired subsequent 2DG-induced feeding, presumably due to alloxan's toxic effects, but did 337 not impair the hyperglycemic response to 2DG (30, 38) . Similarly, Phl injections into 4V have been 338
shown to stimulate feeding, but not hyperglycemia (11). Moreover, we have reported that 4V drug-339 induced activation of AMPK stimulated feeding and that inhibition of AMPK significantly delayed the 340 onset of systemic 2DG-induced feeding (25), but in unpublished results from this same study, we 341 found that neither stimulation nor blockade of AMPK phosphorylation altered blood glucose levels. 342
Finally, the mobilization of glucose and the stimulation of feeding are responses to glucose deficit that 343 have been shown to require separate populations of catecholamine neurons (35). Therefore, it would 344 not be surprising to find that these functionally distinct catecholamine cell populations are controlled 345 by different glucose-sensing mechanisms and circuitry. 346
Data reported here indicating a differential effectiveness of U0126 in blocking the 347 catecholamine-dependent feeding responses to GcA, but not to Phl or 5TG, is interesting in several 348 respects. First, the blockade of GcA-induced feeding by U0126 suggests that the postsynaptic effects 349 of catecholamine neurons required for GcA-induced feeding, like those required for secretion of 350 corticotrophin-releasing hormone in response to 2DG-induced glucoprivation and insulin-induced 351 hypoglycemia (19), may be transduced by the MEK/ERK1/2 signaling cascade. Secondly, differential 352 dependence of 5TG, GcA and Phl on MEK signaling for the feeding effect may indicate that these 353 substances exert their effects on different catecholaminergic cell populations, as discussed above. 354
Alternatively GcA-activated neurons may have inputs to NE and E neurons that are chemically distinct 355 from inputs activated by 5TG or Phl. 356
357
PERSPECTIVES AND SIGNIFICANCE 358
We found that both 4V and LV injections of GcA, Phl and 5TG increased food intake, but only 359 5TG triggered a hyperglycemic response. We conclude from our results that food intake is controlled 360 by multiple glucose monitoring mechanisms some of which do not depend on monitoring of 361 glycolysis. By contrast, central control of blood glucose appears to depend exclusively on monitoring 362 of glycolysis. However, despite differences in their cellular mechanisms of action, the effects of all 363 three agents on food intake were abolished by lesion of hindbrain catecholamine neurons that project 364 to the medial hypothalamus, the same lesion that abolishes stimulation of feeding by systemic 2DG 365 and by insulin-induced hypoglycemia. It is not yet clear whether the control of food intake by multiple 366 glucose sensing mechanisms depends on convergence of mechanistically distinct glucose sensing cells 367 onto hindbrain catecholamine neurons or whether hindbrain catecholamine neurons themselves express 368 multiple distinct glucose sensing mechanisms. Further study of neuronal responses to agents such as 369
GcA, Phl and 5TG will yield important information regarding the localization, circuitry and specific 370 roles of the multiple glucose sensors that participate in control of food intake and other functions 371 important for maintenance of local and overall glucose homeostasis. control solution was injected into 4V or LV of normal rats and food intake was measured during the 507 subsequent 4 hr period. Both 4V and LV injections of GcA significantly stimulated food intake (*P < 508 0.05, vs control). n = 6 -9 and 7 -8 rats per group, for 4V and LV injection, respectively. B, GcA 509 (0.6 mg/rat) or aCSF control was injected into 4V or LV in SAP and DSAP rats. Food intake during 4 510 hr after the injection was measured. SAP treated rats increased their food intake significantly in 511 response to both 4V and LV GcA, but DSAP rats did not increase intake in response to GcA. *P < 512 0.01, vs SAP control. For 4V injections, n = 7 -9; for LV injections, n= 6 -8 rats per group. 513 514   FIG. 3 . Effects of GcA on blood glucose concentrations. GcA (0.6 mg/rat) or the aCSF control 515 solution was injected into the 4V or LV of normal rats and blood glucose levels were measured before 516 and 5 hr after the injection. GcA did not increase blood glucose above control levels after injection into 517 either ventricle (P > 0.8, and P > 0.2 for 4V and LV injections, respectively; n = 5, 6 rats per group, 518 respectively). 519 FIG. 4 . Effects of phloridzin (Phl) on feeding. A, Phl (56.25, 112.5, or 225 .0 µg/rat) and vehicle 521 control solution (50% DMSO in saline) were injected into 4V or LV of normal rats and food intake 522 during 4 hr after the injection was measured. Phl significantly stimulated food intake after both LV 523 and 4V injections of the two higher doses (*P < 0.01, vs control for both LV and 4V). For 4V 524 injections, n = 10 -11 rats per treatment, and for LV injections, n= 8 -12 rats per treatment. B, Phl 525 (112.5 µg/rat) or vehicle control was injected into 4V or LV in SAP and DSAP rats. Food intake 526 during 4 hr after the injection is shown. *P < 0.001, vs. SAP control. For 4V and LV injections, 527 respectively, n = 8 -9 and 6 -8 rats per group. 528 529 FIG. 5. Effects of Phl on blood glucose concentrations. Phl (112.5 µg/rat) or the DMSO vehicle 530 solution (Control) was injected into 4V or LV and blood glucose levels were measured before and 531 during the 5 hr period after the injection. Phl did not increase blood glucose levels above those 532 obtained after DMSO (P > 0.08, and P > 0.2 between treatments for 4V and LV injections, 533 respectively; n = 6 -7 rats per group). 534 535 FIG. 6. Effects of 5TG on feeding and blood glucose concentrations. Control vehicle or 5TG (135 536 µg/rat) and was injected into 4V or LV in SAP and DSAP rats. On separate test days, food intake was 537 measured during a 4 hr test and blood glucose was measured 1 hr after injections in the absence of 538 food. A, food intake (left panel) and blood glucose concentrations (right panel) after 4V injections. *P 539 < 0.001, vs SAP control or DSAP control; n = 5 -6, and 11 rats per group for feeding and blood 540 glucose test, respectively. B, food intake (left panel) and blood glucose concentrations (right panel) 541 after LV injections. *P < 0.001, vs SAP control or DSAP control; n = 6, and 6 -8 rats per group for 542 feeding and blood glucose test, respectively. 543
FIG. 7.
Effects of the MEK inhibitor, U0126, on feeding and blood glucose. A, effects of U0126 on 545 4V GcA-induced feeding. U0126 (1 µg/rat) was injected into 4V, 30 min before GcA (0.6 mg/rat) 546 injection. Food intake during 4 hr after the GcA injection is shown. *P < 0.01, vs. control; n = 8 -9 547 rats per group. B, effects of U0126 on 4V Phl-induced feeding. U0126 (1 µg/rat) was injected into 4V 548 30 min before Phl (112.5 µg/rat) injection. Food intake during 4 hr after the Phl injection is shown. *P 549 < 0.01, vs. control; n = 7 -10 rats per group. C, effects of U0126 on 4V 5TG-induced feeding (left 550 panel) and blood glucose (right panel). U0126 (6 µg/rat) was injected into 4V, 30 min before 5TG (135 551 µg/rat) injection. Food intake (during 4 hr period) and blood glucose concentrations at 1 hr after the 552 5TG injection are shown. *P < 0.001, vs. control; n = 6 rats per group for feeding and blood glucose 553 tests. 554
